« Return to News | CROs/Service Providers

Quintiles Cuts Ribbon On New Research Facility

Friday, May 25, 2007 12:30 PM

North Carolina-based CRO Quintiles has opened a new four-story, 236,000-square-foot clinical research facility in Overland Park, Kan. The facility will replace the company’s Clinical Development Services and Clinical Pharmacology units located in Kansas City, Mo., as well a an early phase unit in Lenexa, Kan. The new phase I facility will be three times the space, consisting of 150 beds and room for up to 200 more staff. Quintiles already employs about 750 employees in the Kansas City area.

The unit was dedicated in a ceremony by company founder and chief executive officer Dennis Gillings and David Kerr, Secretary of the Kansas Department of Commerce. Also in attendance were Thomas Thornton, president and chief executive officer of the Kansas Bioscience Authority, and Carl Gerlach, mayor of Overland Park.

"Ultimately, however, this building is about even more than the creation of jobs in Overland Park and the growth of Quintiles," Gillings said. "It is about improving healthcare -- for people in Kansas, across the United States and around the world." 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.